Akebia Ther
$ 0.95
-26.02%
06 Aug - close price
- Market Cap 264,470,000 USD
- Current Price $ 0.95
- High / Low $ 1.01 / 0.85
- Stock P/E N/A
- Book Value 0.12
- EPS -0.06
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.79 %
- 52 Week High 3.44
- 52 Week Low 0.82
About
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$4.20
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-07 | 2026-02-26 | 2025-11-10 | 2025-08-07 | 2025-05-08 | 2025-03-13 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-14 | 2023-11-08 |
| Reported EPS | -0.02 | -0.03 | -0.05 | 0.002 | 0.0267 | 0.02 | -0.1 | -0.1 | -0.04 | -0.08 | 0.0032 | -0.08 |
| Estimated EPS | -0.03 | -0.02 | -0.03 | -0.04 | -0.02 | -0.04 | -0.075 | -0.05 | -0.05 | -0.09 | -0.04 | -0.08 |
| Surprise | 0.01 | -0.01 | -0.02 | 0.042 | 0.0467 | 0.06 | -0.025 | -0.05 | 0.01 | 0.01 | 0.0432 | 0 |
| Surprise Percentage | 33.3333% | -50% | -66.6667% | 105% | 233.5% | 150% | -33.3333% | -100% | 20% | 11.1111% | 108% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AKBA
2026-08-05 23:11:14
Akebia Therapeutics (NASDAQ: AKBA) reported its Q2 2026 earnings, highlighting a significant 60% year-over-year increase in Vafseo revenue to $21.3 million, driven by over 10,500 active patients. The company also announced that its VOICE trial for Vafseo met its interim stopping criteria, demonstrating a statistically significant reduction in mortality and hospitalization. Despite these successes, total revenue declined to $49.1 million due to generic competition impacting Auryxia sales, and the company anticipates a potential decline in Vafseo revenue in 2027 due to pricing reductions after its TDAPA period ends.
2026-08-05 23:11:14
This article is a transcript of Akebia Therapeutics, Inc.'s Q2 2026 Earnings Call held on August 5, 2026. The content provides details from the call, including an operator's message, but the full transcript is reserved for subscribers. It also lists recent news and financial performance data for Akebia Therapeutics (AKBA).
2026-08-05 20:15:54
Akebia Therapeutics announced strong second-quarter 2026 financial results, with Vafseo net product revenues growing to $21.3 million and over 10,500 patients on therapy. The company also highlighted significant advancements in its rare kidney disease pipeline, including the initiation of a Phase 2 trial for ebribafusp and positive interim analysis from the VOICE trial demonstrating improved safety outcomes for Vafseo. Despite a net loss due to decreased Auryxia revenues and increased expenses, Akebia expects its cash resources and revenues to fund operations for at least two years.
2026-08-03 22:41:43
Akebia Therapeutics Inc is anticipated to report a loss of 4 cents per share. This information comes from a Refinitiv earnings preview. The full article is available through a TradingView subscription.
2026-08-03 19:41:43
Akebia Therapeutics (Nasdaq: AKBA) granted stock options for an aggregate of 61,000 shares to two new employees on July 31, 2026. These inducement awards, granted under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $1.32 per share and will vest over four years, subject to continued employment. This move aims to incentivize and retain key talent within the biopharmaceutical company focused on kidney disease.
2026-08-03 16:05:00
Akebia Therapeutics, Inc. (Nasdaq: AKBA) reported granting options to purchase 61,000 shares of common stock to two new employees on July 31, 2026. These grants, made as an inducement for employment, comply with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $1.32 per share. The options vest over four years, with 25% vesting after the first year and the remainder vesting quarterly thereafter, contingent on continued employment.
